Brief: Arch Biopartners Receives Government Of Canada Funding To Support Phase II Therapeutic Trial Of Metablok For Covid-19
15/12/2020 19:10
Dec 15 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES GOVERNMENT OF CANADA FUNDING TO
SUPPORT PHASE II THERAPEUTIC TRIAL OF METABLOK FOR COVID-19
* ARCH BIOPARTNERS INC - CANADA AWARDED A CONTRIBUTION OF UP
TO
$6.7 MILLION TO SUPPORT PHASE II DEVELOPMENT OF METABLOK
Source text for Eikon: ID:nGNX9NNjGF
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide